Adenoviral Pneumonia During Etanercept Treatment in a Patient with Rheumatoid Arthritis

Inhibitors of tumor necrosis factor-alpha (TNF-α) have been approved for treating rheumatoid arthritis. As one of the biological response modifiers, etanercept has also been used in the treatment of psoriatic arthritis and inflammatory bowel disease. While etanercept is effective, certain infectious...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Min-Jung, Kim, Myung-Sin, Choi, Eun-Hwa, Lee, Kyoung-Eun, Kim, You-Kyoung, Choi, Hee-Jung
Formato: Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2007
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687603/
https://www.ncbi.nlm.nih.gov/pubmed/17427651
http://dx.doi.org/10.3904/kjim.2007.22.1.63
Descripción
Sumario:Inhibitors of tumor necrosis factor-alpha (TNF-α) have been approved for treating rheumatoid arthritis. As one of the biological response modifiers, etanercept has also been used in the treatment of psoriatic arthritis and inflammatory bowel disease. While etanercept is effective, certain infectious complications, such as tuberculosis, fungus, and cytomegalovirus, have been reported. We report the first Korean case of adenoviral pneumonia in a 55-year-old female who developed disseminated adenoviral infection following etanercept treatment, which resolved after anti-TNF-α discontinuation.

Ejemplares similares